• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型氟喹诺酮RO 23-6240(AM-833)的体外活性

In vitro activity of RO 23-6240 (AM-833): a new fluoroquinolone.

作者信息

Fass R J, Helsel V L

出版信息

Diagn Microbiol Infect Dis. 1987 Apr;6(4):293-9. doi: 10.1016/0732-8893(87)90178-7.

DOI:10.1016/0732-8893(87)90178-7
PMID:3107872
Abstract

The in vitro activities of RO 23-6240 (AM-833) and four comparative fluoroquinolones were studied. Minimal inhibitory concentrations (MICs) of RO 23-6240, which inhibited at least 90% of strains, were less than or equal to 0.03-1 microgram/ml for Staphylococcus aureus, Staphylococcus epidermidis, Enterobacteriaceae, Acinetobacter anitratus Aeromonas hydrophila, Branhamella catarrhalis, and Haemophilus influenzae, 2-8 micrograms/ml for Staphylococcus saprophyticus, streptococci, diphtheroids, and Pseudomonas spp., and 1-32 micrograms/ml for anaerobic species. MICs of ofloxacin, pefloxacin, norfloxacin, and ciprofloxacin paralleled those of RO 23-6240. With all five drugs, MICs were minimally affected by inoculum size and minimal bacterial concentrations (MBCs) were always within two dilution steps (log2) of MICs.

摘要

对RO 23 - 6240(AM - 833)和四种对照氟喹诺酮类药物的体外活性进行了研究。RO 23 - 6240对至少90%菌株具有抑制作用,其对金黄色葡萄球菌、表皮葡萄球菌、肠杆菌科细菌、鲍氏不动杆菌、嗜水气单胞菌、卡他布兰汉菌和流感嗜血杆菌的最低抑菌浓度(MIC)小于或等于0.03 - 1微克/毫升,对腐生葡萄球菌、链球菌、类白喉杆菌和假单胞菌属的MIC为2 - 8微克/毫升,对厌氧菌的MIC为1 - 32微克/毫升。氧氟沙星、培氟沙星、诺氟沙星和环丙沙星的MIC与RO 23 - 6240的MIC相似。对于所有这五种药物,接种量对MIC的影响极小,且最小杀菌浓度(MBC)始终在MIC的两个稀释步骤(log2)范围内。

相似文献

1
In vitro activity of RO 23-6240 (AM-833): a new fluoroquinolone.新型氟喹诺酮RO 23-6240(AM-833)的体外活性
Diagn Microbiol Infect Dis. 1987 Apr;6(4):293-9. doi: 10.1016/0732-8893(87)90178-7.
2
The comparative in-vitro activity of eight newer quinolones and nalidixic acid.八种新型喹诺酮类药物与萘啶酸的体外活性比较
J Antimicrob Chemother. 1986 Nov;18 Suppl D:1-20. doi: 10.1093/jac/18.supplement_d.1.
3
Comparative in-vitro activity of Ro 23-6240, a new trifluorinated quinolone.
J Antimicrob Chemother. 1987 Sep;20(3):363-72. doi: 10.1093/jac/20.3.363.
4
In vitro activity of the new 4-quinolone compound Ro 23-6240.新型4-喹诺酮化合物Ro 23-6240的体外活性
Eur J Clin Microbiol. 1987 Apr;6(2):161-4. doi: 10.1007/BF02018199.
5
Comparative in vitro activity of RO 23-6240 (fleroxacin), a new 4-quinolone derivative.新型4-喹诺酮衍生物RO 23-6240(氟罗沙星)的体外活性比较
Eur J Clin Microbiol. 1987 Aug;6(4):482-5. doi: 10.1007/BF02013116.
6
[In vitro antibacterial activity of 2 new quinolones: A 56619 (difloxacin) and A 56620. Comparison with pefloxacin, ofloxacin and ciprofloxacin].[两种新型喹诺酮类药物的体外抗菌活性:A 56619(双氟沙星)和A 56620。与培氟沙星、氧氟沙星和环丙沙星的比较]
Pathol Biol (Paris). 1987 Jun;35(5 Pt 2):759-67.
7
Comparative in vitro activities of pefloxacin, ofloxacin, enoxacin and ciprofloxacin against 256 clinical isolates.培氟沙星、氧氟沙星、依诺沙星和环丙沙星对256株临床分离株的体外活性比较
Acta Pathol Microbiol Immunol Scand B. 1987 Apr;95(2):141-6. doi: 10.1111/j.1699-0463.1987.tb03102.x.
8
Comparative in vitro activity of amifloxacin and five other fluoroquinolone antimicrobial agents and preliminary criteria for the disk susceptibility test.阿米氟沙星与其他五种氟喹诺酮类抗菌剂的体外活性比较及纸片药敏试验的初步标准。
Eur J Clin Microbiol. 1987 Apr;6(2):179-82. doi: 10.1007/BF02018204.
9
RO 23-6240 (AM-833), a new fluoroquinolone: in vitro antimicrobial activity and tentative disk diffusion interpretive criteria.
Diagn Microbiol Infect Dis. 1987 May;7(1):29-35. doi: 10.1016/0732-8893(87)90066-6.
10
Comparative in vitro activity of ciprofloxacin, ofloxacin and pefloxacin against resistant clinical isolates.环丙沙星、氧氟沙星和培氟沙星对耐药临床分离株的体外活性比较
Chemioterapia. 1987 Apr;6(2):75-8.

引用本文的文献

1
Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.氟罗沙星。对其在各种感染中的药理学及治疗效果的综述。
Drugs. 1995 May;49(5):794-850. doi: 10.2165/00003495-199549050-00010.
2
In vitro antistaphylococcal activity of pefloxacin alone and in combination with other antistaphylococcal drugs.培氟沙星单独及与其他抗葡萄球菌药物联合使用时的体外抗葡萄球菌活性。
Antimicrob Agents Chemother. 1987 Oct;31(10):1457-60. doi: 10.1128/AAC.31.10.1457.
3
Fleroxacin clinical pharmacokinetics.氟罗沙星的临床药代动力学。
Clin Pharmacokinet. 1992 Feb;22(2):116-31. doi: 10.2165/00003088-199222020-00003.